

Half-Year Highlights



“It was a very good first half, with positive news from the pipeline and continued strong sales growth in both Pharmaceuticals and Diagnostics.”

Severin Schwan, CEO Roche Group

Key financials

CHF **23.6** BILLION

Group sales **+6%**

CHF **18.4** BILLION

Pharmaceuticals sales **+5%**

CHF **5.2** BILLION

Diagnostics sales **+7%**

CHF **9.2** BILLION

Core operating profit **+7%**¹

CHF **7.22**

Core earnings per share **+7%**¹

Group



- Strategic partnership with Foundation Medicine to advance personalised healthcare
- Acquisition of Trophos to expand into neuromuscular disease
- Acquisition of Ariosa to develop pre-natal testing
- Newsweek magazine ranks Roche ninth out of 500 companies in Top Green Companies
- Roche named Top Employer Europe 2015

Diagnostics



- FDA approval of a three-virus blood screening test for HIV, HCV and HBV
- Strong uptake of new cobas 6800 and 8800
- Elecsys HTLV-I/II test launched
- US approval for the cobas KRAS mutation test on the cobas 4800 system
- Strep A bacterial test launched in point-of-care setting

Pharmaceuticals



- Avastin with chemotherapy approved in the EU for advanced cervical cancer
- Lucentis approved in the US for diabetic retinopathy
- Positive results for Perjeta in early HER2-positive breast cancer
- Pivotal study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin's lymphoma

Pipeline



- Ocrelizumab showed remarkable improvements over a standard-of-care medicine in relapsing forms of multiple sclerosis
- Cancer immunotherapy candidate atezolizumab delivered positive study results in lung, breast and bladder cancer
- More positive data on the combination of cobimetinib and Zelboraf in advanced melanoma
- Three FDA Breakthrough Therapy Designations

All growth rates in this document are at constant exchange rates (CER; average full-year 2014).

¹ This increase excludes the benefit of 428m Swiss francs before tax related to the divestment of filgrastim rights in 2014.